Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation

Wang, Lei; Wu, Xianping; Yang, Ge; Hu, Nan; Zhao, Zijian; Zhao, Lei; Li, Shengyu

doi:10.1016/j.neuroscience.2022.06.036

Cited by 22 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 56 Likewise, the second study showed that CBD and L-dopa independently and significantly increased avoidance times of the shock, representing learnt behaviour, compared with the control PD group. 49 …”

Section: Resultsmentioning

confidence: 99%

“…Cannabinoid interventions from included studies varied from cannabinoid receptor (CBR) agonists such as HU308, CBD, WIN55,212–2, HU210, nabilone, THC, CP55,940, ACEA, CBGA-quinone (CBGA-Q), GW842166x and AM1241,20 23 24 26–52 endocannabinoid enzyme inhibitors (FAAH and MAGL) which increase available endocannabinoids such as JZL184, URB597, KML29, PF-3945,19 21 22 25 29 34 45 53–56 a putative endocannabinoid, noladin ether which is an endocannabinoid agonist,32 57 58 an endocannabinoid modulator blocking anandamide reuptake called AM40459 preserves the supply of endocannabinoids and beta-caryophellene, which is a terpene commonly found in cannabis 60…”

Section: Resultsmentioning

confidence: 99%

“…URB597 had a selective reduction in hyperkinesia but not psychosis overall. The other two studies investigated learning and cognitive function by measuring the step-down test 49 56. Both studies used toxin PD animal models, either MPTP49 or 6-OHDA 56.…”

Section: Resultsmentioning

confidence: 99%

“…The other two studies investigated learning and cognitive function by measuring the step-down test 49 56. Both studies used toxin PD animal models, either MPTP49 or 6-OHDA 56. The mice were trained to learn to step down from the platform in order to avoid an electrical shock prior to administering the toxin.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesCannabis has been proposed as a potential treatment for Parkinson’s disease (PD) due to its neuroprotective benefits. However, there has been no rigorous review of preclinical studies to evaluate any potential treatment effect. This systematic review was undertaken to provide evidence in support or against a treatment effect of cannabinoids in animal models of PD.MethodsDatabases were searched for any controlled comparative studies that assessed the effects of any cannabinoid, cannabinoid-based treatment or endocannabinoid transport blocker on behavioural symptoms in PD animal models.ResultsA total of 41 studies were identified to have met the criteria for this review. 14 of these studies were included in meta-analyses of rotarod, pole and open field tests. Meta-analysis of rotarod tests showed a weighted mean difference of 31.63 s for cannabinoid-treated group compared with control. Meta-analysis of pole tests also showed a positive treatment effect, evidenced by a weighted mean difference of −1.51 s for cannabinoid treat group compared with control. However, meta-analysis of open field test demonstrated a standardised mean difference of only 0.36 indicating no benefit.ConclusionThis review demonstrates cannabinoid treatment effects in alleviating motor symptoms of PD animal models and supports the conduct of clinical trials of cannabis in PD population. However, there is no guarantee of successful clinical translation of this outcome because of the many variables that might have affected the results, such as the prevalent unclear and high risk of bias, the different study methods, PD animal models and cannabinoids used.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, the animals treated with CBD showed increased tyrosine hydroxylase (TH) expression in the substantia nigra. In addition, they upregulated the expression of Bcl-2, decreasing the levels of Bax and Caspase-3 and preventing the expression of the NLRP3/caspase-1/IL-1β inflammasome pathway [ 68 ]. Patients affected with PD, in general, make use of L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precursor drug, which helps treat motor impairments at least in the first and middle phases of the disorder, but without interrupting the course of the disease [ 69 ].…”

Section: Cannabinoids Use In Late Lifementioning

confidence: 99%

Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges

et al. 2022

View full text Add to dashboard Cite

The use of cannabinoids as therapeutic drugs has increased among aging populations recently. Age-related changes in the endogenous cannabinoid system could influence the effects of therapies that target the cannabinoid system. At the preclinical level, cannabidiol (CBD) induces anti-amyloidogenic, antioxidative, anti-apoptotic, anti-inflammatory, and neuroprotective effects. These findings suggest a potential therapeutic role of cannabinoids to neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer. Emerging evidence suggests that CBD and tetrahydrocannabinol have neuroprotective therapeutic-like effects on dementias. In clinical practice, cannabinoids are being used off-label to relieve symptoms of PD and AD. In fact, patients are using cannabis compounds for the treatment of tremor, non-motor symptoms, anxiety, and sleep assistance in PD, and managing responsive behaviors of dementia such as agitation. However, strong evidence from clinical trials is scarce for most indications. Some clinicians consider cannabinoids an alternative for older adults bearing Parkinson’s disease and Alzheimer’s dementia with a poor response to first-line treatments. In our concept and experience, cannabinoids should never be considered a first-line treatment but could be regarded as an adjuvant therapy in specific situations commonly seen in clinical practice. To mitigate the risk of adverse events, the traditional dogma of geriatric medicine, starting with a low dose and proceeding with a slow titration regime, should also be employed with cannabinoids. In this review, we aimed to address preclinical evidence of cannabinoids in neurodegenerative disorders such as PD and AD and discuss potential off-label use of cannabinoids in clinical practice of these disorders.

show abstract

The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD

Chu,

Wang,

et al. 2024

Inflamm. Res.

View full text Add to dashboard Cite

Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation

Cited by 22 publications

References 38 publications

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges

The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD

Contact Info

Product

Resources

About